PsiOxus expects to recruit around 132 cachectic patients with colorectal and lung cancer in centers in Europe and Asia.
The trial is designed to demonstrate reversal of weight loss following treatment with MT-102 but will also examine improvement in functional ability and quality of life as quantified by a battery of previously validated instruments.
PsiOxus CEO John Beadle said MT-102 is unique in that it reduces muscle breakdown (catabolism) as well as increasing muscle build-up (anabolism).
"This clinical trial aims to demonstrate this Anabolic Catabolic Transforming activity in the context of late stage cancer patients," Beadle said.